Zenosense, Inc. (ZENO) Pre-Commercial Lung Cancer Detection Device Manufacturing Underway
Zenosense, a healthcare technology company principally engaged in developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, announced it has manufactured a pre-commercial prototype device. The device is expected to be evaluated for the detection of lung cancer in exhaled breath. The work involved in the prototyping process has been entrusted to the company's contracted development partner Zenon Biosystem ("Zenon"), a component of the Sgenia group. In line with the protocol design for an anticipated lung cancer detection trial, two pre-commercial devices are currently being manufactured with the identical design,…